Patent application number | Description | Published |
20090089229 | MOBILE BRAIN-BASED DEVICE HAVING A SIMULATED NERVOUS SYSTEM BASED ON THE HIPPOCAMPUS - A brain-based device (BBD) having a physical mobile device NOMAD controlling and under control by a simulated nervous system. The simulated nervous system is based on an intricate anatomy and physiology of the hippocampus and its surrounding neuronal regions including the cortex. The BBD integrates spatial signals from numerous objects in time and provides flexible navigation solutions to aid in the exploration of unknown environments. As NOMAD navigates in its real world environment, the hippocampus of the simulated nervous system organizes multi-modal input information received from sensors on NOMAD over timescales and uses this organization for the development of spatial and episodic memories necessary for navigation. | 04-02-2009 |
20090093049 | Methods of Identifying Synthetic Transcriptional and Translational Regulatory Elements, and Compositions Related to Same - Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements. | 04-09-2009 |
20110022230 | HYBRID CONTROL DEVICE - A brain-based device (BBD) for moving in a real-world environment has sensors that provide data about the environment, actuators to move the BBD, and a hybrid controller which includes a neural controller having a simulated nervous system being a model of selected areas of the human brain and a non-neural controller based on a computational algorithmic network. The neural controller and non-neural controller interact with one another to control movement of the BBD. | 01-27-2011 |
20110047109 | Brain-Based Device Having a Cerebellar Model for Predictive Motor Control - A mobile brain-based device (BBD) includes a mobile platform with sensors and effectors, which is guided by a simulated nervous system that is an analogue of the cerebellar areas of the brain used for predictive motor control to determine interaction with a real-world environment. The simulated nervous system has neural areas including precerebellum nuclei (PN), Purkinje cells (PC), deep cerebellar nuclei (DCN) and an inferior olive (IO) for predicting turn and velocity control of the BBD during movement in a real-world environment. The BBD undergoes training and testing, and the simulated nervous system learns and performs control functions, based on a delayed eligibility trace learning rule. | 02-24-2011 |
20110071968 | MOBILE BRAIN-BASED DEVICE HAVING A SIMULATED NERVOUS SYSTEM BASED ON THE HIPPOCAMPUS - A brain-based device (BBD) having a physical mobile device NOMAD controlling and under control by a simulated nervous system. The simulated nervous system is based on an intricate anatomy and physiology of the hippocampus and its surrounding neuronal regions including the cortex. The BBD integrates spatial signals from numerous objects in time and provides flexible navigation solutions to aid in the exploration of unknown environments. As NOMAD navigates in its real world environment, the hippocampus of the simulated nervous system organizes multi-modal input information received from sensors on NOMAD over timescales and uses this organization for the development of spatial and episodic memories necessary for navigation. | 03-24-2011 |
20110124100 | TRANSLATION ENHANCER-ELEMENT DEPENDENT VECTOR SYSTEMS - A translation enhancer-driven positive feedback vector system is disclosed which is designed to facilitate identification of a Translational Enhancer Element (TEE) and to provide a means for overexpression of gene products. The system exploits both transcriptional and translational approaches to control the expression levels of genes and/or gene products. Methods are also disclosed for screening libraries of random nucleotide sequences to identify translational elements and for overproduction of proteins, which have uses in both research and industrial environments. | 05-26-2011 |
20110184556 | MOBILE BRAIN-BASED DEVICE FOR USE IN A REAL WORLD ENVIRONMENT - A mobile brain-based device BBD includes a mobile base equipped with sensors and effectors (Neurally Organized Mobile Adaptive Device or NOMAD), which is guided by a simulated nervous system that is an analogue of cortical and sub-cortical areas of the brain required for visual processing, decision-making, reward, and motor responses. These simulated cortical and sub-cortical areas are reentrantly connected and each area contains neuronal units representing both the mean activity level and the relative timing of the activity of groups of neurons. The brain-based device BBD learns to discriminate among multiple objects with shared visual features, and associated “target” objects with innately preferred auditory cues. Globally distributed neuronal circuits that correspond to distinct objects in the visual field of NOMAD 10 are activated. These circuits, which are constrained by a reentrant neuroanatomy and modulated by behavior and synaptic plasticity, result in successful discrimination of objects. The brain-based device BBD is moveable, in a rich real-world environment involving continual changes in the size and location of visual stimuli due to self-generated or autonomous, movement, and shows that reentrant connectivity and dynamic synchronization provide an effective mechanism for binding the features of visual objects so as to reorganize object features such as color, shape and motion while distinguishing distinct objects in the environment. | 07-28-2011 |
20120173020 | MOBILE BRAIN-BASED DEVICE FOR USE IN A REAL WORLD ENVIRONMENT - A mobile brain-based device BBD includes a mobile base equipped with sensors and effectors (Neurally Organized Mobile Adaptive Device or NOMAD), which is guided by a simulated nervous system that is an analogue of cortical and sub-cortical areas of the brain required for visual processing, decision-making, reward, and motor responses. The brain-based device BBD learns to discriminate among multiple objects with shared visual features, and associated “target” objects with innately preferred auditory cues. The brain-based device BBD is moveable, in a rich real-world environment involving continual changes in the size and location of visual stimuli due to self-generated or autonomous, movement, and shows that reentrant connectivity and dynamic synchronization provide an effective mechanism for binding the features of visual objects so as to reorganize object features such as color, shape and motion while distinguishing distinct objects in the environment. | 07-05-2012 |
20120209432 | HYBRID CONTROL DEVICE - A brain-based device (BBD) for moving in a real-world environment has sensors that provide data about the environment, actuators to move the BBD, and a hybrid controller which includes a neural controller having a simulated nervous system being a model of selected areas of the human brain and a non-neural controller based on a computational algorithmic network. The neural controller and non-neural controller interact with one another to control movement of the BBD. | 08-16-2012 |
20130274919 | MOBILE BRAIN-BASED DEVICE FOR USE IN A REAL WORLD ENVIRONMENT - A mobile brain-based device BBD includes a mobile base equipped with sensors and effectors (Neurally Organized Mobile Adaptive Device or NOMAD), which is guided by a simulated nervous system that is an analogue of cortical and sub-cortical areas of the brain required for visual processing, decision-making, reward, and motor responses. The brain-based device BBD learns to discriminate among multiple objects with shared visual features, and associated “target” objects with innately preferred auditory cues. The brain-based device BBD is moveable, in a rich real-world environment involving continual changes in the size and location of visual stimuli due to self-generated or autonomous, movement, and shows that reentrant connectivity and dynamic synchronization provide an effective mechanism for binding the features of visual objects so as to reorganize object features such as color, shape and motion while distinguishing distinct objects in the environment. | 10-17-2013 |
20130309682 | Ribosomal Polynucleotides and Related Expression Systems - Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described. | 11-21-2013 |
20150152437 | Chromosomal Landing Pads and Related Uses - Provided herein are methods for stable integration and/or expression of one or more recombinant polynucleotides in a host cell. The recombinant polynucleotides are typically integrated into the host genome at some native chromosomal integration sites. The integration can be mediated by homologous recombination or by using a hybrid recombinase targeting the specific chromosomal locations. The native chromosomal integration sites in the host cells, which support stable integration and strong transcription activities of foreign genes, are present within or adjacent to specific genes in the CHO genome, ankyrin 2 gene (Ank2), cleavage and polyadenylation specific factor 4 gene (Cpsf4), C-Mos gene, and Nephrocystin-1/Mal gene. Also provided are methods and nucleic acid molecules for inserting site-specific recombination sequences (chromosomal landing pads) into these specific chromosomal locations. Further provided are engineered host cells which contain chromosomal landing pads or transgenes integrated into the native chromosomal integration sites. Further provided are methods and compositions (e.g., kits) for integrating and expressing heterologous polynucleotides in host cells bearing inserted chromosomal landing pads. | 06-04-2015 |
20150267190 | TRANSLATIONAL ENHANCER-ELEMENT DEPENDENT VECTOR SYSTEMS - A translation enhancer-driven positive feedback vector system is disclosed which is designed to facilitate identification of a Translational Enhancer Element (TEE) and to provide a means for overexpression of gene products. The system exploits both transcriptional and translational approaches to control the expression levels of genes and/or gene products. Methods are also disclosed for screening libraries of random nucleotide sequences to identify translational elements and for overproduction of proteins, which have uses in both research and industrial environments. | 09-24-2015 |
Patent application number | Description | Published |
20090254160 | Automated Temperature Contrast and Dynamic Pressure Modules for a Hot or Cold Wrap Therapy System - The present invention relates to a replaceable module for use with a thermal contrast therapy systems. The replaceable module may be an automated thermal contrast therapy module which includes a casing, a manual mixing valve, an automated mixing valve, an automated mixing valve actuator, a temperature sensor, and an interface. A cold and a hot fluid are mixed to generate a therapy fluid. The therapy fluid may be output to a therapy bladder. The second replaceable module is a compression therapy module which includes a casing, an air pump, a pneumatic solenoid, and a pressure monitor. The casing may include a pressurized air pathway including an air outlet. The pump may pressurize the air within the pathway, and the solenoid may regulate the air pressure using feedback from the pressure sensor. Additionally, a pressure relief valve may release pressure if it gets above a safety threshold. The compression therapy module may also include a fluid pathway. | 10-08-2009 |
20100030306 | Therapeutic Cranial Wrap for a Contrast Therapy System - The present invention relates to a therapeutic cranial wrap for use with a thermal contrast therapy systems and methods for providing a temperature regulated fluid. The cranial wrap includes an active thermal exchange bladder and an active compression bladder, adapted to fit the cranial therapy site. The thermal exchange bladder may be coupled to the thermal contrast therapy system. The compression bladder may compress the therapy site. In some embodiments, the compressive bladder may be integrated into the thermal exchange bladder, or may be omitted. The cranial wrap also includes a contoured shell, known as a hood shaped therapy pad, which is adapted to snugly fit the cranial therapy site and provide neck support. Adjustable straps, including at least one strap that circumvents the cranium, secure the cranial wrap in a fitted position adjacent the therapy site. The cranial wrap couples to the thermal contrast therapy system which includes a hot and cold fluid reservoir, a mixing valve, and a fluid pump. | 02-04-2010 |
20100137765 | System and Methods for an Interchangeable Lumbar Contrast Therapy Pad - The present invention relates to a spinal column brace system which includes a rigid support, an interchangeable therapy pad, and a front panel. The rigid support includes patches of hook material and also has straps connected to it. These straps are at least partially elastic and also include hook material pads on their ends. The interchangeable therapy pad, on the other hand, has one side covered in loop material, thereby allowing the therapy pad to be attached to the patches on the rigid support. The front panel is also covered in loop material, which may be used to couple to the hook material found on the straps. The therapy pad includes a thermal exchange bladder and a cushion layer. The thermal exchange bladder may be coupled to a contrast therapy system via an umbilical and fluid coupler. The contrast therapy system includes a hot and cold reservoir. A mixing valve may mix a selected ratio of the hot and cold fluids from the hot and cold reservoirs to make therapy fluid of a particular temperature. A fluid pump then delivers the therapy fluid to the thermal exchange bladder. | 06-03-2010 |
20130245519 | DEEP VEIN THROMBOSIS ("DVT") AND THERMAL/COMPRESSION THERAPY SYSTEMS, APPARATUSES AND METHODS - A pressure therapy system includes an air pump; a pneumatic line pressurized by the air pump; and a cuff in fluid communication with the pneumatic line, the cuff including flaps sized and shaped to extend around a user's limb, a first chamber and a second chamber separated fluidly by the cuff from the first chamber, wherein the pneumatic line splits into first and second line segments or openings, the first line segment or opening communicating fluidly with the first separated chamber, the second line segment or opening communicating fluidly with the second separated chamber, and wherein the second line segment or opening or a pathway of the cuff leading to the second separated chamber includes a flow restricting structure that delays pressurized air from reaching the second chamber relative to the first chamber. | 09-19-2013 |
20130245729 | COLD THERAPY SYSTEMS AND METHODS - A cold therapy system including a cooling bath; a therapy pad in fluid communication with the cooling bath; a pump positioned and arranged to pump water from the cooling bath to the therapy pad and back to the cooling bath; and a control unit controlling the pump, the control unit programmed to operate the pump according to a cycle in which the pump is operated at less than maximum to cause the therapy pad temperature to be raised and to conserve a cooling resource within the cooling bath. | 09-19-2013 |
Patent application number | Description | Published |
20090082321 | STEROID CONTAINING DRUG DELIVERY SYSTEMS - Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed. | 03-26-2009 |
20090196906 | Kinase inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 08-06-2009 |
20090208557 | Kinase inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 08-20-2009 |
20090286773 | Kinase inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 11-19-2009 |
20110077229 | Steroid Containing Drug Delivery Systems - Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed. | 03-31-2011 |
20110263611 | Kinase Inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 10-27-2011 |
20120065178 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES - Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described. | 03-15-2012 |
20120207810 | Kinase Inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 08-16-2012 |
20120238558 | Kinase inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 09-20-2012 |
20130123223 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES - The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. | 05-16-2013 |
20130123226 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES - The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). | 05-16-2013 |
20130172353 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS - This invention is directed to a compound of Formula I | 07-04-2013 |
20130210862 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS - Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions. | 08-15-2013 |
20130267497 | KINASE INHIBITORS - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 10-10-2013 |
20140031408 | Biodegradable Intravitreal Tyrosine Kinase Implants - Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions. | 01-30-2014 |
20140357609 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES - Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described. | 12-04-2014 |
20150057258 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES - The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. | 02-26-2015 |
20150265633 | STEROID CONTAINING DRUG DELIVERY SYSTEM - Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed. | 09-24-2015 |